COO: Mixed Signals for The Cooper Companies, Inc.

The Cooper Companies, Inc. is a global medical device company operating through two segments: 'CooperVision' and 'CooperSurgical'. 'CooperVision' develops, manufactures, and markets a range of contact lenses, including single-use, two-week, and monthly lenses, such as the 'MiSight 1 day' lens for myopia management, and brands like 'Biofinity', 'MyDay', and 'clariti 1 day'. Their target market includes contact lens wearers worldwide, focusing on addressing vision challenges like astigmatism, presbyopia, and myopia. 'CooperSurgical' offers products and services for fertility and women's health, including medical devices used in gynecology and obstetrics, contraception ('Paragard' IUD), fertility products for IVF, and cryopreservation services. Their target markets are medical offices, ambulatory surgery centers, hospitals, and fertility clinics. The company differentiates itself through a diversified portfolio, strategic acquisitions, and collaboration with healthcare professionals to deliver innovative technologies and improved clinical outcomes.

No relevant news was found for this stock today.

COO's technical outlook is mildly bearish. The recent price action shows a significant downtrend, with the price declining from approximately $74 in late July to around $69 as of November 4th. The stock price is trading below its 50-day SMA, currently at 69.40, and significantly below its 200-day SMA of 77.23, reinforcing the bearish trend. Momentum indicators also signal weakness. The MACD is negative, with the MACD line (0.33) below the signal line (0.77), and the RSI is at 46.09, indicating bearish momentum but not yet oversold. The stochastic oscillator (20.33) is very low. The ADX is at 17.48, which suggests a weak trend. The recent price drop below the lower Bollinger Band suggests potential for a short-term bounce, but the overall trend remains down. Given the persistent downtrend and bearish momentum, COO is likely to experience further downside in the coming 1-3 months.

Cooper Companies' MD&A presents a mixed but cautiously optimistic picture. `Net Sales` for CooperVision increased by 6% in the three months ended July 31, 2025, compared to 2024, reaching $718.4 million, driven by toric and multifocal lenses (up 10%) and sphere lenses (up 3%). CooperSurgical's `Net Sales` also increased by 4% to $341.9 million, driven by office and surgical (up 3%) and fertility (up 6%). The consolidated `Gross Profit` margin, however, decreased to 65% from 66% due to inventory write-offs related to a product line exit. Cash flow from operating activities increased to $548.2 million for the first nine months of fiscal 2025, compared to $441.2 million in the prior year, attributed to increases in net income and deferred income taxes. The company repurchased 0.7 million shares for $52.2 million during the quarter. Management states they are 'optimistic about the long-term prospects' but acknowledge 'significant risks and uncertainties' including global economic conditions, foreign exchange fluctuations, and regulatory developments, which 'could further adversely affect our future sales, cash flow and performance'. They believe current cash, future cash flow, and available credit will be 'sufficient to meet our anticipated cash needs' for at least the next 12 months.

The Cooper Companies' Q3 2025 earnings call reveals a mixed performance with revenue below expectations despite margin improvements and double-digit earnings growth. Al White noted that Q3 consolidated revenues were up 5.7% year-over-year, or 2% organically, to $1.06 billion, but 'revenues were lower than expected'. CooperVision's revenue came in below expectations, driven by a decline in Clarity lens sales and weakness in the pure play e-commerce segment in Asia Pacific. While MyDay delivered double-digit growth, the increase in fitting sets and trial lenses impacted Clarity orders. CooperSurgical posted revenue growth of 4.5%, or 2% organically, but faces pressure in the fertility market. Looking ahead to Q4, guidance reflects continued headwinds from Clarity, with CooperVision and CooperSurgical both guided to 2% to 4% organic growth. The company is also undertaking restructuring activities to improve efficiency and leverage prior investments. Brian Andrews mentioned that they are 'currently executing several productivity and efficiency initiatives' to position themselves for a strong 2026. While the company expects stronger free cash flow in the future, the near-term outlook is tempered by market challenges and the ongoing transition between product lines.

COO's financial performance presents a somewhat neutral picture. Revenue has shown an overall increase, starting from $931.6M in Q1 2024 and reaching $1060.3M in Q3 2025, indicating positive top-line growth. However, the gross profit ratio has fluctuated, starting at 0.6156 in Q1 2024, peaking at 0.6996 in Q3 2025, suggesting some variability in profitability. Operating cash flow figures are only available for Q2 2025 ($96.2M), Q1 2025 ($190.6M), Q4 2024 ($268.1M), Q3 2024 ($207.5M), Q2 2024 ($111M) and Q1 2024 ($122.7M) making it difficult to assess a clear trend. Total debt has decreased from $2772.3M in Q1 2024 to $2478.3M in Q3 2025, indicating improved solvency and reduced financial risk. The company's net income has remained relatively stable. Overall, while revenue is growing and debt is decreasing, the fluctuations in gross profit ratio and the need for more recent operating cash flow data points create uncertainty about the company's financial trajectory over the next 6-12 months.

The company demonstrates a moderately bullish profile, characterized by solid revenue growth and improving profitability. Revenue has consistently increased, indicating strong market demand. The gross margin exhibits stability, suggesting efficient cost management. Return on Equity (ROE) has shown positive movement, signaling enhanced profitability and efficient use of shareholder equity. The Price-to-Earnings (P/E) ratio, while elevated, might be justifiable given the growth trajectory and positive ROE trend. The Debt-to-Equity ratio shows a slight increase, which warrants monitoring, but is counterbalanced by a healthy Current Ratio, implying sufficient liquidity to meet short-term obligations. Overall, the company presents a favorable picture with growth and profitability, though the leverage should be watched closely. The combination of growth and profitability suggests potential for continued positive performance over the next 12 months.